Posttransplant Malignancies in Adult Renal and Hepatic Transplant Patients
Authors:
- 1 August 2020
- journal article
- research article
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 18 (4) , 470-473
Abstract
Objectives: The risk of some cancer types increases after organ transplant compared with that shown in the general population; this has been well documented in clinical studies. With patients having longer survival and with the higher number of transplant procedures, cancer is an increasing health concern at high-volume transplant centers. Malignancy has an important effect on short- and long-term graft and patient survival. In this study, we evaluated cancer frequency during transplant patient follow-up. Materials and Methods: This single-center retrospective study included patients who underwent solid-organ transplant at the Baskent University Medical Faculty Hospital from 1997 to 2017. Renal and hepatic transplant patients older than 16 years at the time of transplant and diagnosed with cancer after transplant were included the study. In total, 1176 of 2018 renal transplant recipients and 274 of 548 hepatic transplant recipients met the inclusion criteria. Results: We determined that 52 of 1176 renal transplant (4.5%) and 9 of 274 hepatic transplant patients (3.3%) developed posttransplant cancer during followup. Of 61 total patients with cancer posttransplant, 44 were males (72.1%) and 17 were females (27.9%), with median age at transplant of 39.2 years. Overall, the incidence of cancer in transplant recipients was 4.2%. The most frequent cancers were basal and squamous skin cancers, which were seen in 18 patients (29%), and Kaposi sarcoma, which was seen in 11 patients (18%). Of the 61 patients who developed cancer, 43 (70%) were still alive at the time of this study. Conclusions: Despite recent positive developments in the use of immunosuppressive drugs, posttransplant malignancy is still a health problem. Fortunately, most cancers in this patient group have good prognosis and can be cured by surgical resection. Transplant physicians should aim for early detection of these diseases.Keywords
This publication has 16 references indexed in Scilit:
- Burden of de novo malignancy in the liver transplant recipientLiver Transplantation, 2012
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry AuditAmerican Journal of Transplantation, 2010
- Screening of Donor and Recipient Prior to Solid Organ TransplantationAmerican Journal of Transplantation, 2009
- Cancer incidence and risk factors after solid organ transplantationInternational Journal of Cancer, 2009
- Evaluation of Posttransplantation Malignancies Compared With De Novo TumorsTransplantation Proceedings, 2007
- Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantationTransplant International, 2007
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- Pre-emptive Treatment for Cytomegalovirus Viremia to Prevent Cytomegalovirus Disease in Solid Organ Transplant RecipientsTransplantation, 2006
- Management of chronic viral hepatitis before and after renal transplantationTransplantation, 2002